EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery

Henri Chédotal iD, Katrine Povlsen, Dilip Narayanan, Charlotte H Gotfredsen, Michael Gajhede, Anders Bach iD, Mads H Clausen iD

ChemMedChem · 14.07.2026 · 21 (13)

DOI: 10.1002/cmdc.70365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 03.07.2026. Verfasst von Henri Chédotal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark. Hauptthemen laut MEDLINE: Receptors, Tumor Necrosis Factor, Type I, Drug Discovery, Small Molecule Libraries. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danmarks Frie Forskningsfond, Villum Fonden, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor necrosis factor receptor 1 (TNFR1) plays a major role in immunoregulation. It is involved in inflammatory and autoimmune diseases like rheumatoid arthritis, psoriasis, Alzheimer’s disease, and multiple sclerosis. However, few small‐molecule inhibitors of TNFR1 have been reported, even though they constitute a good alternative to already existing antibody therapies targeting the TNF pathway. Here, we report the discovery of a new class of molecules for the extracellular domain of TNFR1 using a fragment‐based approach through primary screening by NMR spectroscopy, followed by orthogonal validation by surface plasmon resonance (SPR) and X‐ray crystallography. Guided by these results, we have synthesized 46 analogs with micromolar potency showing up to ∼10‐fold improved affinity toward TNFR1 compared to the fragment hits. These results can provide a structural basis for the discovery of novel TNFR1 inhibitors in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Tumor Necrosis Factor, Type IDrug DiscoverySmall Molecule LibrariesLigandsHumansCrystallography, X-RaySurface Plasmon ResonanceStructure-Activity RelationshipProtein DomainsMolecular StructureModels, MolecularDose-Response Relationship, Drug

Stichwörter der Autor:innen

NMRSPRTNFR1fragment‐based screeningprotein crystallography

Substanzen

Receptors, Tumor Necrosis Factor, Type ILigandsSmall Molecule Libraries

Autor:innen und Institutionen

  • Department of Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark.
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Henri Chédotal, Anders Bach, Mads H Clausen

Förderung

  • Danmarks Frie Forskningsfond
  • Villum Fonden
  • Novo Nordisk Fonden
  • Carlsbergfondet
  • Vetenskapsrådet
  • VINNOVA
  • Svenska Forskningsrådet Formas

Zitieren

APA

Chédotal, H., Povlsen, K., Narayanan, D., Gotfredsen, C. H., Gajhede, M., Bach, A., & Clausen, M. H. (2026). Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70365

Vancouver

Chédotal H, Povlsen K, Narayanan D, Gotfredsen CH, Gajhede M, Bach A, et al. Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70365

BibTeX
@article{Chdotal2026,
  author = {Chédotal, Henri and Povlsen, Katrine and Narayanan, Dilip and Gotfredsen, Charlotte H and Gajhede, Michael and Bach, Anders and Clausen, Mads H},
  title = {Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70365}
}
Kostenlos starten →